trigram

This is a table of type trigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.

trigram	frequency
in patients with	619
the treatment of	442
patients with covid	441
treatment of covid	377
cq and hcq	356
severe acute respiratory	289
for the treatment	281
acute respiratory syndrome	265
the use of	263
respiratory syndrome coronavirus	228
chloroquine and hydroxychloroquine	196
display the preprint	191
who has granted	191
license to display	191
medrxiv a license	191
the preprint in	191
to display the	191
has granted medrxiv	191
hydroxychloroquine and azithromycin	191
a license to	191
granted medrxiv a	191
in the treatment	189
of hydroxychloroquine in	184
the copyright holder	184
the risk of	183
copyright holder for	179
holder for this	179
systemic lupus erythematosus	176
the author funder	170
is the author	170
as well as	159
this version posted	157
of patients with	155
preprint in perpetuity	154
with or without	153
a systematic review	148
patients treated with	146
is made available	145
of cq and	144
for this preprint	143
it is made	141
made available under	141
available under a	141
international license it	139
license it is	139
en pacientes con	138
treated with hcq	133
of hydroxychloroquine and	130
randomized clinical trial	128
hospitalized patients with	120
in combination with	120
use of hcq	118
patients with severe	114
pacientes con covid	113
of chloroquine and	112
under a is	111
a is the	111
hcq and cq	109
the effect of	109
of severe acute	108
this preprint this	108
preprint this version	108
due to the	108
which was not	103
hydroxychloroquine in patients	102
of hcq in	99
of hcq and	98
in hospitalized patients	98
with severe covid	96
efficacy and safety	95
of cq hcq	95
of action of	93
certified by peer	91
by peer review	91
not certified by	91
was not certified	91
of these drugs	90
el uso de	89
as a treatment	89
intensive care unit	88
systematic review and	87
cq or hcq	85
and safety of	84
in this study	83
effect of hcq	83
for treatment of	82
respiratory distress syndrome	81
de los pacientes	80
was associated with	78
acute respiratory distress	78
in order to	77
the control group	77
in the hcq	76
critically ill patients	76
a total of	75
in treatment of	75
followed by mg	75
is associated with	75
treatment of severe	75
one of the	75
the combination of	74
p r e	74
o o f	73
a l p	73
j o u	73
u r n	73
it has been	73
r n a	73
l p r	73
p r o	73
n a l	73
o u r	73
use of hydroxychloroquine	73
r o o	73
associated with a	72
treated with hydroxychloroquine	72
a treatment of	72
the efficacy of	72
mechanism of action	70
effects of chloroquine	70
based on the	70
mg twice daily	69
and azithromycin as	69
review and meta	69
dose of mg	69
been shown to	68
with coronavirus disease	68
azithromycin as a	67
and azithromycin in	67
efficacy of hydroxychloroquine	66
results of an	66
a combination of	66
in vitro antiviral	66
for patients with	66
patients in the	65
hydroxychloroquine and chloroquine	65
included in the	64
this article is	64
increased risk of	64
of the patients	64
of an open	63
all rights reserved	63
vitro antiviral activity	63
los pacientes con	63
or in combination	63
con sospecha o	63
qt interval prolongation	63
of hydroxychloroquine for	63
the qt interval	62
a randomized clinical	62
hydroxychloroquine for the	62
alone or in	60
there was no	60
of coronavirus disease	60
of the disease	60
east respiratory syndrome	59
results of a	59
to evaluate the	58
the time of	58
middle east respiratory	58
study of hydroxychloroquine	58
torsade de pointes	57
treatment with hydroxychloroquine	57
the management of	57
patients with coronavirus	56
in vitro and	56
the efficacy and	55
mild to moderate	55
ill patients with	55
review of the	55
antiviral activity and	55
the number of	55
world health organization	55
mechanisms of action	54
the context of	54
the role of	54
the effects of	54
in the control	54
dosing design of	53
of optimized dosing	53
design of hydroxychloroquine	53
with systemic lupus	53
projection of optimized	53
the hcq group	53
en los pacientes	53
of the study	53
and projection of	53
optimized dosing design	53
standard of care	53
activity and projection	53
hcq with or	52
for coronavirus disease	52
version posted june	52
en el paciente	52
combination of hydroxychloroquine	52
with hydroxychloroquine and	52
hcq in covid	51
randomized controlled trial	51
treatment with hcq	51
efficacy of hcq	51
treatment of patients	50
and hydroxychloroquine in	50
has been shown	50
use of cq	49
at the time	49
infection in vitro	49
protected by copyright	49
de pacientes con	49
is protected by	49
the presence of	49
article is protected	49
the results of	49
mortality in patients	49
in systemic lupus	49
or without azithromycin	49
with rheumatoid arthritis	49
hcq has been	48
to assess the	48
patients with sars	48
of novel coronavirus	48
gautret et al	48
in the context	48
and hcq in	48
according to the	47
in addition to	47
combination with azithromycin	47
compared to the	47
in inhibiting sars	47
antiviral activity of	46
the absence of	46
patients infected with	46
was used to	46
antiviral effects of	46
no significant difference	45
and hcq are	45
systematic review of	45
found to be	45
the united states	45
used in the	45
in terms of	45
of qtc prolongation	44
of a randomized	44
effects of hcq	44
observational study of	44
hydroxychloroquine in hospitalized	44
no evidence of	44
risk of bias	44
were treated with	44
risk factors for	43
has been reported	43
the fact that	43
of hcq on	43
the lack of	43
de la enfermedad	43
daily for days	42
safety and efficacy	42
treatment for covid	42
el riesgo de	42
on the other	42
patients with rheumatoid	42
vitro and in	41
effective in inhibiting	41
a less toxic	41
patients hospitalized with	41
twice daily for	41
effectively inhibit the	40
higher risk of	40
the antiviral effects	40
hospitalized with covid	40
the recently emerged	40
derivative of chloroquine	40
qt prolongation and	40
of the drugs	40
in new york	40
emerged novel coronavirus	40
there is no	40
torsades de pointes	40
vero e cells	40
retrospective cohort study	40
remdesivir and chloroquine	40
the host cell	40
in clinical studies	40
inhibit the recently	39
dose of hcq	39
the other hand	39
associated pneumonia in	39
and chloroquine effectively	39
less toxic derivative	39
clinical characteristics of	39
toxic derivative of	39
chloroquine effectively inhibit	39
is effective in	39
effect of hydroxychloroquine	39
recently emerged novel	39
of the drug	39
in critically ill	38
as compared to	38
used to treat	38
of the virus	38
of treatment with	38
has shown apparent	37
and in vivo	37
patients with systemic	37
use of chloroquine	37
combination of hcq	37
apparent efficacy in	37
of critically ill	37
the development of	37
the two groups	37
small sample size	37
shown apparent efficacy	37
pneumonia in clinical	37
efficacy in treatment	37
se recomienda no	37
food and drug	37
chloroquine phosphate has	36
en el grupo	36
there is a	36
for this this	36
preprint the copyright	36
this this version	36
the novel coronavirus	36
both cq and	36
between the two	36
the present study	36
and drug administration	36
systematic reviews and	36
and treatment of	36
was found to	36
in patients treated	36
the need for	36
pharmacokinetics of hydroxychloroquine	36
phosphate has shown	36
clinical efficacy of	36
effect of chloroquine	36
patients with mild	36
in the study	36
version posted november	36
of chloroquine on	36
hospitalized with severe	35
hcq and azithromycin	35
qt interval in	35
with severe acute	35
has also been	35
hydroxychloroquine in the	35
effects of cq	35
of hospitalized patients	35
and efficacy of	34
de la salud	34
in a patient	34
a patient with	34
hcq and rfifn	34
of qt interval	34
hydroxychloroquine with or	34
in vitro studies	34
tumor necrosis factor	34
of clinical trials	34
used for the	34
a retrospective cohort	34
a dose of	34
significant difference in	33
the inhibition of	33
effect of a	33
version posted may	33
supplementary table s	33
type i ifn	33
time to clinical	33
than that of	33
of this study	33
the incidence of	33
with at least	33
not associated with	33
the mechanism of	33
in patients hospitalized	33
infected with sars	32
any of the	32
for cq and	32
the replication of	32
shown to be	32
risk of qt	32
of the viral	32
novel coronavirus pneumonia	32
el manejo de	32
most of the	32
the case of	32
treatment of sars	32
an increase in	32
of the included	32
side effects of	32
hcq in the	32
it should be	32
patients receiving hcq	31
the expression of	31
human immunodeficiency virus	31
role in the	31
with novel coronavirus	31
pacientes con sospecha	31
of hcq is	31
during the covid	31
the most common	31
and hcq have	31
the world health	31
the effectiveness of	31
the intensive care	31
interval in patients	31
of the literature	31
action of hydroxychloroquine	31
the production of	30
number of patients	30
la presencia de	30
in rheumatoid arthritis	30
potent inhibitor of	30
azithromycin in covid	30
an increased risk	30
with the combination	30
has not been	30
the viral load	30
of cq or	30
yao et al	30
se recomienda la	30
on the efficacy	30
the first day	30
the rate of	30
with hcq and	30
mg per day	30
in the early	30
involved in the	30
a randomized trial	30
have been reported	30
the activation of	30
was defined as	30
hospital mortality in	30
use of these	30
the safety of	29
outcomes of hydroxychloroquine	29
rheumatoid arthritis and	29
increase the risk	29
at least a	29
of hcq was	29
clinical trials are	29
at a dose	29
of a combination	29
activity against sars	29
the majority of	29
in the absence	29
randomized controlled trials	29
to treat covid	29
there are no	29
have shown that	29
in clinical trials	29
mg daily for	28
randomized clinical trials	28
the severe acute	28
or clinical benefit	28
with the use	28
de cuidados intensivos	28
randomised controlled trial	28
due to its	28
with use of	28
prophylaxis for covid	28
management of covid	28
least a six	28
of the studies	28
patients with at	28
patients who received	28
well as the	28
los pacientes que	28
there was a	28
to clinical improvement	28
day follow up	28
in severe covid	28
in the lung	28
association of treatment	28
reviews and meta	28
in the united	28
the duration of	27
of the sars	27
the coronavirus disease	27
inhibitor of sars	27
the immune system	27
safety of hcq	27
is important to	27
clearance or clinical	27
of sars coronavirus	27
increase in the	27
series of patients	27
the impact of	27
of hydroxychloroquine with	27
a higher risk	27
been reported to	27
evidence for the	27
emergency use authorization	27
conflict of interest	27
of hcq with	27
a pilot study	27
related to the	27
effect of cq	27
as shown in	27
as adjunctive therapy	27
microbiological effect of	26
the course of	26
with hydroxychloroquine or	26
of chloroquine against	26
chloroquine or hydroxychloroquine	26
this study was	26
drugs in the	26
viral shedding duration	26
there were no	26
who received hcq	26
hydroxychloroquine or azithromycin	26
benefit with the	26
in treating covid	26
or azithromycin with	26
have also been	26
a novel coronavirus	26
a potent inhibitor	26
to the control	26
effects of hydroxychloroquine	26
version posted july	26
need to be	26
it is important	26
and microbiological effect	26
to have a	26
compared to those	26
mode of action	26
studies have shown	26
azithromycin in patients	26
in vitro activity	26
evidence of rapid	26
associated with the	26
clinical and microbiological	26
some of the	26
patients who were	26
of the treatment	26
controlled clinical trials	25
wang et al	25
in animal models	25
new york state	25
the qtc interval	25
per day for	25
chloroquine is a	25
in the management	25
in light of	25
hcq in patients	25
a number of	25
of hydroxychloroquine on	25
the safety and	25
be associated with	25
these drugs in	25
as a result	25
associated with use	25
clinical benefit with	25
treated with cq	25
was no significant	25
qtc prolongation in	25
antiviral clearance or	25
have been shown	25
in the case	25
chloroquine for the	25
shown in figure	25
showed that the	25
a case series	25
azithromycin with in	25
were included in	25
the antiviral activity	25
of rapid antiviral	25
rapid antiviral clearance	25
in a recent	25
the possibility of	24
a pilot observational	24
a review of	24
patients with a	24
of the data	24
case series of	24
and hydroxychloroquine as	24
an old drug	24
has been used	24
trial of hydroxychloroquine	24
the release of	24
moderate coronavirus disease	24
sars coronavirus infection	24
pilot observational study	24
teniendo en cuenta	24
congestive heart failure	24
the end of	24
the ph of	24
on the use	24
was not associated	24
hydroxychloroquine or chloroquine	24
analysis of the	24
a randomized controlled	24
to be effective	24
the original paper	24
cases of covid	24
who did not	23
of hydroxychloroquine as	23
associated with an	23
implications for rheumatology	23
the study was	23
serious adverse events	23
and rheumatoid arthritis	23
the primary outcome	23
with mild to	23
prolongation associated with	23
cq hcq in	23
been associated with	23
due to covid	23
treatment of malaria	23
it is also	23
hcq alone or	23
for the management	23
coronavirus infection and	23
hcq and az	23
of hcq for	23
recomienda no utilizar	23
of hcq to	23
should not be	23
para el manejo	23
activation of the	23
not included in	23
paciente con sospecha	23
infection treated with	23
in vitro in	23
during the first	23
novel coronavirus in	23
between hcq and	23
risk of adverse	23
did not show	23
cov and sars	23
activity of cq	23
of convalescent plasma	23
acute lung injury	23
pilot study of	23
of the hcq	23
of patients infected	22
was not peer	22
institutional review board	22
study of patients	22
in this review	22
patients testing positive	22
hcq have been	22
cq has been	22
was observed in	22
the severity of	22
inhibition of the	22
hydroxychloroquine in treatment	22
in the covid	22
we did not	22
the included studies	22
in patients receiving	22
of adverse events	22
el grupo de	22
hospitalized for covid	22
effects of the	22
en caso de	22
use in covid	22
associated with hcq	22
is a potent	22
infection and spread	22
mg kg day	22
therapy for patients	22
of chloroquine in	22
the in vitro	22
difference in the	22
data from the	22
as a potential	22
appears to be	22
se recomienda que	22
in the present	21
of the covid	21
of this drug	21
qt interval and	21
to be a	21
a recent study	21
a reduction in	21
el paciente con	21
none of the	21
corrected qt interval	21
are needed to	21
factors associated with	21
action of cq	21
that of the	21
mortality in covid	21
of the two	21
testing positive for	21
risk of death	21
patients with acute	21
and outcomes of	21
of the qt	21
of systemic lupus	21
of qt prolongation	21
ongoing clinical trials	21
due to their	21
chloroquine and hcq	21
la necesidad de	21
risk of mortality	21
and systemic lupus	21
a clinical trial	21
day for days	21
of the pandemic	21
a retrospective analysis	21
resulted in a	21
in hospitalized covid	21
to reduce the	21
of severe covid	21
of observational studies	21
to moderate coronavirus	21
hydroxychloroquine in covid	21
diseases such as	21
that there was	21
connective tissue diseases	21
and in the	21
of chloroquine diphosphate	21
and mortality in	20
were found to	20
hcq for the	20
interval prolongation associated	20
a narrative review	20
the authors declare	20
no significant differences	20
hcq or cq	20
showed that hcq	20
of rheumatoid arthritis	20
among hospitalized patients	20
hydroxychloroquine usage in	20
in adults hospitalized	20
of the first	20
a author funder	20
course of covid	20
results showed that	20
doses of hcq	20
was performed using	20
has been demonstrated	20
usage in united	20
is based on	20
in the first	20
united states veterans	20
viral load in	20
the outcome of	20
to our knowledge	20
patients with mainly	20
hcq was associated	20
in united states	20
was used for	20
associated with increased	20
seems to be	20
patients hospitalized for	20
veterans hospitalized with	20
mainly mild to	20
type i interferon	20
states veterans hospitalized	20
adverse effects of	20
el tratamiento de	20
significant effect of	20
early treatment of	20
it is not	20
drugs have been	20
be due to	20
of antimalarial drugs	20
pneumonia in wuhan	20
el inicio de	20
morbidity and mortality	20
with respect to	20
on patients with	20
under a author	20
of lopinavir ritonavir	20
approved by the	20
of hydroxychloroquine usage	20
with hydroxychloroquine azithromycin	20
an observational study	20
with mainly mild	20
of chloroquine for	20
activity of hcq	20
of torsade de	19
could not be	19
del paciente con	19
en un estudio	19
prophylactic and therapeutic	19
that the use	19
for the prevention	19
use authorization for	19
diphosphate as adjunctive	19
chloroquine on viral	19
administration of hcq	19
sudden cardiac death	19
can be used	19
of hydroxychloroquine sulfate	19
needs to be	19
combination with other	19
adjunctive therapy for	19
concomitant azithromycin among	19
should be noted	19
feline infectious peritonitis	19
for mechanical ventilation	19
are associated with	19
and azithromycin on	19
of type i	19
as a prophylactic	19
of patients were	19
mg bid for	19
de la uci	19
or hcq with	19
hospitalized patients testing	19
pacientes con sdra	19
such as the	19
hcq use in	19
caused by the	19
the treatment group	19
old drug against	19
is one of	19
azithromycin among hospitalized	19
prolongation of the	19
significant differences in	19
chloroquine diphosphate as	19
to inhibit the	19
in coronavirus disease	19
therapy in covid	19
on viral infections	19
each of the	19
of cq in	19
or without concomitant	19
with azithromycin in	19
cardiac side effects	19
without concomitant azithromycin	19
in the liver	19
for patients hospitalized	19
lupus erythematosus and	19
in accordance with	19
also been reported	19
vitro in vitro	19
compared with the	19
were observed in	19
the findings of	19
the availability of	19
novel coronavirus disease	19
de pointes in	19
por lo tanto	19
positive for coronavirus	19
no utilizar de	18
glycosylation of ace	18
low doses of	18
hcq did not	18
paciente con covid	18
lower than that	18
the prevention of	18
and qt prolongation	18
in the high	18
for systematic reviews	18
as postexposure prophylaxis	18
on the first	18
no conflict of	18
t cells and	18
coronary artery disease	18
be used to	18
the comparison group	18
doses of chloroquine	18
with a macrolide	18
en el tratamiento	18
reported to be	18
the occurrence of	18
of lpv r	18
of these studies	18
a trial of	18
qtc prolongation and	18
because of the	18
by mg twice	18
by hcq and	18
the viral shedding	18
used as a	18
to be more	18
conflicts of interest	18
controlled trial of	18
to moderate covid	18
a cohort of	18
randomized trial of	18
vitro activity against	18
acute respiratory failure	18
to investigate the	18
days of treatment	18
risk of qtc	18
of the most	18
were used to	18
of high vs	18
in vitro inhibition	18
cq and or	18
included in this	18
the binding energy	18
reduction in the	18
for disease control	18
responsible for the	18
effect of high	18
volume of distribution	18
when compared to	18
with rheumatic diseases	18
se recomienda en	18
were performed using	18
ischemic heart disease	18
from patients with	18
polymerase chain reaction	18
are shown in	18
with hcq or	18
preferred reporting items	18
cytokine release syndrome	18
in a study	18
del estado de	18
a retrospective study	18
is mediated by	18
in intensive care	18
efficacy of cq	18
clinical features of	18
a variety of	18
nature of the	18
reporting items for	18
the quality of	18
in our study	18
in vero e	18
and or hcq	18
it is possible	18
large number of	18
analyses were performed	18
the control arm	18
de forma rutinaria	18
of hcq as	18
with acute respiratory	18
the association between	18
clinical trials have	18
de alto flujo	18
the treatment and	18
obtained from the	17
to note that	17
significant difference between	17
safety of hydroxychloroquine	17
the association of	17
vitro inhibition of	17
hydroxychloroquine as postexposure	17
cardiac complications attributed	17
effect of the	17
significant reduction in	17
inicio de los	17
the time to	17
the level of	17
common coronavirus disease	17
de acuerdo con	17
the s protein	17
its ability to	17
to determine the	17
of hcq use	17
has been proposed	17
mediated by the	17
several clinical trials	17
in the hippocampus	17
the need to	17
study showed that	17
reported in the	17
trial of lopinavir	17
for the use	17
clinical course and	17
savarino et al	17
the hcq arm	17
a series of	17
with common coronavirus	17
in the current	17
of the immune	17
these drugs are	17
patients with rheumatic	17
e qt ratio	17
in patients who	17
de la terapia	17
in vitro data	17
insights into the	17
patients with novel	17
patients with common	17
total of patients	17
associated with lower	17
to that of	17
be noted that	17
extracorporeal membrane oxygenation	17
with lopinavir ritonavir	17
long qt syndrome	17
of patients in	17
of hcq or	17
a significant effect	17
and risk factors	17
in the risk	17
the addition of	17
a result of	17
results of the	17
with cq and	17
complications attributed to	17
cq hcq may	17
of viral rna	17
we found that	17
proportion of patients	17
lower respiratory tract	17
have not been	17
be used in	17
analysis was performed	17
m a n	17
an intensive care	17
interval prolongation in	17
been reported in	17
such as systemic	17
of adverse effects	17
adults hospitalized with	17
of mg twice	17
hydroxychloroquine for covid	17
inhibition of human	17
compassionate use of	17
hcq for covid	17
or without a	17
systematic review on	16
there is an	16
in the meta	16
considered to be	16
that in the	16
geleris et al	16
have been proposed	16
treatments for coronavirus	16
been reported that	16
si el paciente	16
prophylaxis of covid	16
vincent et al	16
is known to	16
in a case	16
treatment of novel	16
have been used	16
the corrected qt	16
of hcq treatment	16
it is a	16
of the original	16
showed that cq	16
did not receive	16
high vs low	16
viral replication and	16
y cols en	16
vs low doses	16
on the basis	16
a case report	16
with and without	16
u s c	16
which is a	16
in of patients	16
postexposure prophylaxis for	16
with regard to	16
treated with a	16
the disease course	16
hcq may be	16
interval prolongation and	16
observed in the	16
no reuse allowed	16
in the original	16
in these patients	16
need for mechanical	16
the strength of	16
day followed by	16
a multinational registry	16
absence of a	16
to the intensive	16
multinational registry analysis	16
fuerte a favor	16
data on the	16
at least one	16
with qtc prolongation	16
s c r	16
duration of treatment	16
of patients had	16
prolonged qt interval	16
was shown to	16
r i p	16
uso de la	16
that cq and	16
in the presence	16
c r i	16
should be taken	16
of hcq azm	16
the basis of	16
on the antiviral	16
de cuidado intensivo	16
a n u	16
high risk of	16
there have been	16
be related to	16
the proportion of	16
allowed without permission	16
n u s	16
ritonavir in adults	16
the pharmacokinetics of	16
virus infection in	16
retrospective analysis of	16
of the s	16
replication of sars	16
clinical management of	16
the cardiovascular system	16
admitted to the	16
a report of	16
control and prevention	16
the frequency of	16
reuse allowed without	16
terminal glycosylation of	16
that they have	16
i p t	16
or hcq in	16
into host cells	16
increase in qtc	16
is the most	16
for chloroquine and	16
a new coronavirus	15
a lack of	15
intubation or death	15
in healthy volunteers	15
that there is	15
to be the	15
of the participants	15
been used for	15
are involved in	15
association between hcq	15
safety of cq	15
action of chloroquine	15
what to expect	15
unidad de cuidados	15
a favor fundamento	15
interfere with the	15
been shown that	15
without a macrolide	15
of these patients	15
in vitro study	15
cd t cells	15
insights on the	15
be effective in	15
to be safe	15
binding of the	15
hcq combined with	15
national institutes of	15
with other drugs	15
either cq or	15
as systemic lupus	15
patients were treated	15
se recomienda realizar	15
ingreso a uci	15
the beginning of	15
to examine the	15
added to the	15
studies have been	15
entry into host	15
of hospital stay	15
as a therapeutic	15
with hcq alone	15
in line with	15
by interfering with	15
daily measured qtc	15
those treated with	15
of patients who	15
no se puede	15
have been identified	15
in the prevention	15
disease control and	15
adult patients with	15
an in vitro	15
the binding of	15
is the first	15
found that the	15
presented in table	15
it can be	15
effect on the	15
differences in the	15
la toma de	15
in agreement with	15
ace and tmprss	15
associated with covid	15
cohort study of	15
una serie de	15
part of the	15
safe and effective	15
and hcq is	15
ra and sle	15
prevention of covid	15
hcq or hcq	15
risk of cardiovascular	15
the solidarity trial	15
the mrna expression	15
longest daily measured	15
the included reviews	15
liu et al	15
the ability of	15
and hcq for	15
use of remdesivir	15
azithromycin in the	15
qtc interval prolongation	15
end of the	15
a pesar de	15
analysis of cases	15
this study is	15
modifying antirheumatic drugs	15
the viral replication	15
in relation to	15
for the covid	15
clinical course of	15
the updated meta	15
to the icu	15
no se ha	15
pharmacologic treatments for	15
the study by	15
has been associated	15
to be associated	15
followed by a	15
influenza a virus	15
the influence of	15
or without az	15
a history of	14
expect for covid	14
a mouse model	14
treatments for covid	14
and torsade de	14
may not be	14
lpv r and	14
treatment options for	14
the reduction of	14
cases in marseille	14
of remdesivir in	14
items for systematic	14
the pbs group	14
favor o en	14
to chloroquine and	14
a macrolide for	14
and hcq with	14
replication in vitro	14
macrolide for treatment	14
infected with novel	14
low dose of	14
chloroquine against coronavirus	14
higher than the	14
cq hcq have	14
this is a	14
label use of	14
and management of	14
clinical trial hydroxychloroquine	14
up to days	14
by mg daily	14
or chloroquine with	14
showed no significant	14
was conducted to	14
assessment of qt	14
a favor o	14
that have been	14
patients admitted to	14
to expect for	14
of the qtc	14
studies on the	14
and risk of	14
in vivo studies	14
a global pandemic	14
manejo de la	14
for the novel	14
of patients treated	14
diagnosis and treatment	14
found to have	14
patients with hydroxychloroquine	14
intervals in a	14
was based on	14
likely to be	14
interpretation of the	14
loading dose of	14
effective and safe	14
with a total	14
two of the	14
it may be	14
inhibition of viral	14
chloroquine with or	14
should be considered	14
clinical trials and	14
with an increased	14
of chloroquine or	14
of cases in	14
in case of	14
infection with sars	14
chen et al	14
is required for	14
and severe acute	14
y en el	14
pacientes en el	14
significant qtc prolongation	14
performed using the	14
among patients with	14
patients with diabetes	14
of qt intervals	14
is involved in	14
hydroxychloroquine alone or	14
patient with systemic	14
is responsible for	14
attributed to chloroquine	14
to predict the	14
more likely to	14
corona virus disease	14
the standard of	14
hcq is a	14
entry depends on	14
la carga viral	14
azithromycin on the	14
in rheumatic diseases	14
treatment of coronavirus	14
associated with qtc	14
that cq hcq	14
coronavirus disease in	14
as part of	14
of hcq therapy	14
in the lungs	14
study was conducted	14
and hydroxychloroquine for	14
o en contra	14
mg once daily	14
with hydroxychloroquine alone	14
fact that the	14
the magnitude of	14
of a study	14
the glycosylation of	14
new insights on	14
hcq against sars	14
the hcq treatment	14
patients at risk	14
induced qt prolongation	14
into the host	14
qt intervals in	14
been used in	14
difference between the	14
and mechanical ventilation	14
hydroxychloroquine and its	14
risk factor for	14
cq hcq are	14
tlr and tlr	14
severity of covid	13
there has been	13
servicios de salud	13
that treatment with	13
in cell culture	13
infection and progression	13
the relationship between	13
of the coronavirus	13
in the brain	13
dependent rna polymerase	13
a treatment for	13
patients who did	13
study of the	13
on ace and	13
with lower mortality	13
associated with qt	13
were more likely	13
who require oxygen	13
authors declare no	13
de dificultad respiratoria	13
to be used	13
cytokine storm and	13
recommendations for the	13
course of the	13
in another study	13
we evaluated the	13
in the usa	13
and pharmacokinetics of	13
for use of	13
of the host	13
been found to	13
reported that the	13
is blocked by	13
routine care data	13
los servicios de	13
urgent need for	13
antiviral activity against	13
to compare the	13
change in qtc	13
a range of	13
significantly associated with	13
severely ill patients	13
to estimate the	13
onset of symptoms	13
american college of	13
of hcq has	13
for prophylaxis of	13
to fight covid	13
of all the	13
changes in the	13
features of patients	13
safety of chloroquine	13
in some patients	13
comparative study using	13
the formation of	13
depends on ace	13
in an intensive	13
dentro de las	13
reduction of the	13
with these drugs	13
was obtained from	13
outcomes in patients	13
study using routine	13
lopinavir ritonavir in	13
and it is	13
pneumonia who require	13
calidad de vida	13
effective in the	13
with hcq was	13
the spread of	13
more common in	13
of the infection	13
treatment and prophylaxis	13
critically ill covid	13
important to note	13
shortness of breath	13
of middle east	13
based on a	13
using routine care	13
light of the	13
of the medications	13
ability to inhibit	13
lack of evidence	13
infected with covid	13
be used as	13
patients with pneumonia	13
these two drugs	13
sars and mers	13
the amount of	13
were excluded from	13
el tratamiento con	13
small number of	13
with convalescent plasma	13
the spike protein	13
ph of the	13
with mild covid	13
which this version	13
azithromycin in an	13
results of this	13
yang et al	13
which has been	13
observational comparative study	13
in a mouse	13
of remdesivir for	13
is possible that	13
patients with chronic	13
borba et al	13
use of corticosteroids	13
and cyp a	13
a loading dose	13
be explained by	13
a role in	13
clinical trials in	13
flow nasal cannula	13
the inclusion criteria	13
review on the	13
in a retrospective	13
todos los pacientes	13
arthritis and systemic	13
three times daily	13
for use in	13
a and b	13
prophylaxis and treatment	13
have been published	13
in the literature	13
in the disease	12
associated with reduced	12
immunodeficiency virus type	12
as a possible	12
rheumatoid arthritis patients	12
than cq in	12
through the inhibition	12
benefit of hcq	12
in a randomized	12
therapeutic efficacy of	12
patients received hcq	12
antiviral effect of	12
an analysis of	12
coronavirus in wuhan	12
response to the	12
central nervous system	12
hydroxychloroquine as available	12
erythematosus and rheumatoid	12
defined as the	12
the risk for	12
in which the	12
a reduction of	12
that of cq	12
weapons to fight	12
chronic obstructive pulmonary	12
la disponibilidad de	12
risk of serious	12
compared with placebo	12
an urgent need	12
mayor riesgo de	12
new insights into	12
outcomes of patients	12
higher rate of	12
similar to the	12
for treating covid	12
can result in	12
lupus erythematosus patients	12
the importance of	12
en la uci	12
the general population	12
cell entry depends	12
in subjects with	12
patients on hcq	12
characteristics of the	12
patients were included	12
in comparison with	12
concomitant use of	12
inhibition of sars	12
disease severity and	12
a control group	12
puede emitir una	12
majority of the	12
were obtained from	12
found in the	12
during treatment of	12
studies hydroxychloroquine and	12
a dosis de	12
are presented in	12
of these medications	12
result of the	12
and the risk	12
of hcq against	12
of the manuscript	12
this is the	12
at the same	12
its use in	12
para el uso	12
with a reduction	12
and is blocked	12
leads to the	12
has been found	12
viruses such as	12
of azithromycin and	12
study conducted in	12
characteristics of coronavirus	12
del paciente y	12
we believe that	12
the positive effect	12
was approved by	12
has been suggested	12
en el manejo	12
first case of	12
available weapons to	12
was significantly lower	12
a large number	12
for each of	12
chloroquine in the	12
use of the	12
the activity of	12
of action is	12
and chloroquine in	12
clinically proven protease	12
in the included	12
daily dose of	12
by a clinically	12
and tmprss and	12
studies included in	12
in association with	12
the recovery trial	12
prolongation and torsade	12
se puede emitir	12
hcq on the	12
compared to patients	12
beneficial effect of	12
of hcq mono	12
efficacy of these	12
high dose of	12
clinical trials for	12
the differences in	12
the spike glycoprotein	12
safety profile of	12
to standard care	12
report of cases	12
interfering with the	12
efficacy of chloroquine	12
of the evidence	12
are weak bases	12
without azithromycin in	12
may have been	12
that hcq has	12
the percentage of	12
clinical trials to	12
tissue distribution of	12
risk of cardiac	12
in the plasma	12
creative commons licence	12
in the amygdala	12
entry into the	12
as long as	12
that hcq is	12
the preferred reporting	12
as available weapons	12
blocked by a	12
either alone or	12
personal de salud	12
factores de riesgo	12
a decrease in	12
the two drugs	12
los pacientes en	12
did not have	12
a clinically proven	12
type i fipv	12
greater than ms	12
been demonstrated to	12
across the globe	12
the study period	12
of intubation or	12
high levels of	12
tmprss and is	12
effectiveness of hcq	12
compared to placebo	12
alone and in	12
than in the	12
clinical studies hydroxychloroquine	12
proven protease inhibitor	12
not show any	12
may lead to	12
viral load reduction	12
and of the	12
de pacientes en	12
el de los	12
of these two	12
with a combination	12
studies have reported	12
with hcq in	12
identified as a	12
with the glycosylation	12
that the anti	12
would like to	12
did not find	12
institutes of health	12
been linked to	12
interferes with the	12
hcq was not	12
hcq in combination	12
hepatitis c virus	12
evidence to support	11
this drug is	11
characteristics and outcomes	11
by the spike	11
the scientific community	11
has been observed	11
dosis de mg	11
higher in the	11
have been conducted	11
expression of crh	11
a subset of	11
use of other	11
final de la	11
no significant effect	11
convalescent plasma therapy	11
and the use	11
effects on the	11
the interpretation of	11
shown in table	11
hepatitis b virus	11
s and s	11
the mean age	11
after symptom onset	11
higher rates of	11
factors for mortality	11
and duration of	11
likely to have	11
efficacy of the	11
disease in china	11
the original data	11
the start of	11
is likely to	11
of action and	11
clinical improvement in	11
glycosylation of the	11
of the sprotein	11
treatment in the	11
role of chloroquine	11
among patients who	11
en la mortalidad	11
of cq on	11
hydroxychloroquine as an	11
mg twice a	11
transfer to the	11
creative commons attribution	11
lead to the	11
of systematic reviews	11
and patients with	11
the cytokine storm	11
sobre el uso	11
hydroxychloroquine and covid	11
crh in the	11
risk of covid	11
que los pacientes	11
before and after	11
in this article	11
hcq was found	11
higher proportion of	11
study found that	11
adult inpatients with	11
lessons from the	11
was reported by	11
in the studies	11
it is difficult	11
daily on day	11
el tiempo de	11
utilizar de forma	11
can lead to	11
of bias in	11
shown that the	11
in a small	11
asai et al	11
on day and	11
the creative commons	11
from malaria to	11
all authors have	11
animal toxicity and	11
prolongation in covid	11
drugs for the	11
there is currently	11
into the antiviral	11
and more than	11
trial no evidence	11
is necessary to	11
defined as a	11
mortality rate of	11
patients with moderate	11
found that hcq	11
case of covid	11
hcq has a	11
mortality rate in	11
and severity of	11
in the same	11
angiotensin converting enzyme	11
of which are	11
in clinical practice	11
the data of	11
de salud y	11
at risk for	11
hcq plus az	11
term treatment with	11
and cq have	11
of clinical efficacy	11
in autoimmune diseases	11
had no significant	11
the study of	11
in supplementary table	11
cq hcq on	11
but not in	11
was not significantly	11
cytokines such as	11
was a significant	11
taking into account	11
in the number	11
the antiviral effect	11
the aim of	11
viral load and	11
the active site	11
and in combination	11
was performed to	11
a code for	11
a protective effect	11
at higher risk	11
and cq in	11
prevention and treatment	11
clinical trial clinical	11
in acute respiratory	11
the institutional review	11
the ability to	11
li et al	11
was not different	11
chloroquine and its	11
efficacy against sars	11
the current pandemic	11
this is an	11
on the corrected	11
en el contexto	11
and chloroquine during	11
symptoms of covid	11
with cq or	11
age and gender	11
be more effective	11
con el fin	11
is difficult to	11
those who received	11
in a cohort	11
chronic treatment with	11
twice a day	11
fold increase in	11
data suggest that	11
association of hcq	11
treatment in patients	11
to hcq and	11
positive effect of	11
activity of chloroquine	11
risk of tdp	11
viral entry and	11
the same time	11
of patients from	11
model was used	11
fuera de la	11
at the beginning	11
doses of cq	11
analysis revealed that	11
a study using	11
use for the	11
chloroquine for covid	11
of cytochrome p	11
novel coronavirus from	11
in vitro hydroxychloroquine	11
clinical trial of	11
the purpose of	11
we do not	11
because of its	11
initiation of hcq	11
excluded from the	11
with a code	11
el fin de	11
hcq to treat	11
a day for	11
with pneumonia in	11
in the intensive	11
of viral particles	11
once daily for	11
of t cells	11
resolution of symptoms	11
toxicity and pharmacokinetics	11
of mg kg	11
and its derivative	11
related to covid	11
sample size of	11
prevention and control	11
and congestive heart	11
using routinely collected	11
surviving sepsis campaign	11
lower in the	11
cells of the	11
in a large	11
the patients in	11
suggests that the	11
side effects and	11
of retinal toxicity	11
the first trimester	11
de la vida	11
studies are needed	11
risk of developing	11
obstructive pulmonary disease	11
trial clinical and	11
shown to inhibit	11
risk of hcq	11
ministry of health	11
in any of	11
viral entry into	11
especially in the	11
significant differences between	11
routinely collected data	11
was conducted in	11
no difference in	11
based on these	11
more than one	11
the ace receptor	11
mortality associated with	11
length of hospital	11
stages of the	11
a median of	11
with qt prolongation	11
prior to the	11
and inhibition of	11
been proposed as	11
and hydroxychloroquine are	11
a significant reduction	11
side effect of	11
or treatment of	11
personal protective equipment	10
and use of	10
been suggested as	10
with hcq monotherapy	10
appear to be	10
the objective of	10
thought to be	10
los niveles de	10
these drugs for	10
higher than that	10
in a dose	10
a cohort study	10
patients with ra	10
data to emulate	10
authors declare that	10
as it is	10
drugs for covid	10
compared to control	10
herpes simplex virus	10
en los que	10
suggest that hcq	10
hcq should be	10
in the experimental	10
the initiation of	10
used in combination	10
assessment of the	10
use in the	10
college of cardiology	10
with a median	10
label nonrandomized clinical	10
qt prolongation in	10
and did not	10
in the intervention	10
decreased mortality in	10
stable binding of	10
and prophylaxis of	10
in view of	10
la posibilidad de	10
lee et al	10
adverse events in	10
differences between the	10
hcq and the	10
known to be	10
suggested that the	10
of patients receiving	10
el uso del	10
hcq may also	10
are known to	10
for qtc prolongation	10
inhibits the replication	10
were used for	10
no conflicts of	10
se recomienda el	10
the dose of	10
serie de casos	10
un estudio retrospectivo	10
the mortality rate	10
in vitro efficacy	10
to account for	10
use of this	10
the studies included	10
between the hcq	10
in this context	10
dose of cq	10
for more than	10
related to hcq	10
for age and	10
health commission of	10
mortality of adult	10
more potent than	10
of this article	10
a group of	10
de estos pacientes	10
with a high	10
higher risk for	10
both hcq and	10
severity of illness	10
statement from the	10
la unidad de	10
disease in the	10
diagnosis of covid	10
of human immunodeficiency	10
emulate a target	10
con el uso	10
of this review	10
that of hcq	10
size of the	10
of the human	10
of mg day	10
of corticosteroids in	10
proteolytic processing of	10
that it is	10
trials for the	10
studies showed that	10
states food and	10
days in the	10
para el personal	10
de la mortalidad	10
pacientes que recibieron	10
of the potential	10
cyp a and	10
inflammatory cytokines and	10
mg three times	10
and in vitro	10
a key role	10
study was not	10
use associated with	10
to emulate a	10
clinical trials with	10
inflammatory rheumatic diseases	10
the endosomal ph	10
of chloroquine phosphate	10
por lo que	10
hcq plus azithromycin	10
on in vitro	10
higher probability of	10
the onset of	10
and b cells	10
collected data to	10
decrease in the	10
with human immunodeficiency	10
by increasing the	10
that could be	10
the reference group	10
en cuenta la	10
prolonged viral shedding	10
evidence of clinical	10
are reported in	10
by the fact	10
yet to be	10
en el momento	10
treatment of systemic	10
type ii fipv	10
inpatients with covid	10
an overview of	10
whether or not	10
and acute respiratory	10
with a significant	10
mortality in hospitalized	10
the inflammatory response	10
on viral load	10
el manejo del	10
such as rheumatoid	10
when compared with	10
of our study	10
the progression of	10
of cardiovascular death	10
the drug is	10
efficacy against covid	10
lopinavir ritonavir and	10
los trabajadores de	10
was assessed using	10
significant increase in	10
united states food	10
options for covid	10
in contrast to	10
virus replication in	10
se debe considerar	10
we found no	10
than those in	10
for severe covid	10
con sospecha de	10
pointes in patients	10
been used as	10
the metabolism of	10
cq hcq could	10
se recomienda considerar	10
of tocilizumab in	10
under a perpetuity	10
are likely to	10
of ebola virus	10
did not reduce	10
as rheumatoid arthritis	10
they have no	10
which is the	10
el consentimiento informado	10
on the clinical	10
hcq compared to	10
is not known	10
mhc class ii	10
impact on the	10
cumulative dose of	10
chronic kidney disease	10
are summarized in	10
combined with azithromycin	10
due to hydroxychloroquine	10
could lead to	10
of both cq	10
an antimalarial drug	10
it was not	10
exposure to the	10
bioavailability of hydroxychloroquine	10
the stable binding	10
trial efficacy of	10
shown to have	10
higher in patients	10
an ec of	10
early phase of	10
are currently being	10
adverse event reporting	10
there are several	10
risk of hospitalization	10
is due to	10
as prophylaxis for	10
in patients in	10
centers for disease	10
study conducted by	10
contributed to the	10
pacientes hospitalizados con	10
in the analysis	10
of hydroxychloroquine tablets	10
study using routinely	10
risk of intubation	10
pacientes con enfermedad	10
patients who died	10
a study of	10
of a novel	10
inicio de la	10
of hydroxychloroquine treatment	10
of hcq az	10
the generation of	10
qt prolonging medications	10
patients with autoimmune	10
and sudden death	10
has been a	10
cohort of patients	10
observed in patients	10
nonrandomized clinical trial	10
the study population	10
can be seen	10
q fever endocarditis	10
were transferred to	10
el punto de	10
in adult patients	10
a target trial	10
key role in	10
not yet been	10
we used the	10
heart rhythm society	10
of rheumatic diseases	10
for mortality of	10
and heart failure	10
the small sample	10
se recomienda utilizar	10
upper respiratory tract	10
as evidenced by	10
was added to	10
characteristics of hospitalized	10
the in vivo	10
new york city	10
the lpv r	10
hydroxychloroquine as a	10
with cq hcq	10
patients suspected of	10
evidence of a	10
found that cq	10
of the combination	10
effective in reducing	10
in this meta	10
the potential to	10
the experimental group	10
of adult inpatients	10
and lopinavir ritonavir	10
evaluation of the	10
findings suggest that	10
and antiviral activities	10
se puede considerar	10
a single center	10
did not include	10
course and risk	10
a period of	10
in conjunction with	10
pcr para sars	10
that cq could	9
r and hcq	9
and cardiac arrest	9
plasma levels of	9
of these agents	9
remdesivir for patients	9
critically ill adults	9
of total aes	9
viral replication in	9
en todos los	9
we aimed to	9
in preventing infection	9
patients with confirmed	9
pneumonia in china	9
concentrations in the	9
web of science	9
in the majority	9
no statistically significant	9
incidence of adverse	9
therapy for covid	9
syndrome coronavirus infection	9
when combined with	9
the form of	9
the type of	9
from in vitro	9
coronavirus replication in	9
levels in patients	9
de los casos	9
hcq blood levels	9
the potential for	9
profesionales de la	9
cox proportional hazards	9
to the lack	9
in the blood	9
and side effects	9
within the first	9
prevention or treatment	9
to be considered	9
en pacientes que	9
the result of	9
the intervention arm	9
more than ms	9
the relative risk	9
on days and	9
use of convalescent	9
with autoimmune diseases	9
activity of the	9
la pandemia covid	9
macrophage activation syndrome	9
reported that hcq	9
a statistically significant	9
la incidencia de	9
the survey was	9
reduction of covid	9
up to of	9
associated with acute	9
of remdesivir and	9
a systematic search	9
median age of	9
did not result	9
during the study	9
it is still	9
in these studies	9
associated with sars	9
qtc prolongation was	9
for the diagnosis	9
compared with a	9
hospitalised patients with	9
syndrome coronavirus by	9
outside of the	9
were performed in	9
and torsades de	9
a h n	9
a descriptive study	9
hcq treatment in	9
in response to	9
for the next	9
hydroxychloroquine tablets in	9
in mice and	9
with oxygen requirement	9
clinical benefit of	9
lupus erythematosus hydroxychloroquine	9
drugs to treat	9
hydroxychloroquine use associated	9
the most commonly	9
desde el inicio	9
and have a	9
preliminary results from	9
rbd of sars	9
of cyclic gmp	9
drug for the	9
ec values for	9
in severe cases	9
metabolism of chloroquine	9
for this study	9
in the low	9
analysis of data	9
concentrations of cq	9
mortality in the	9
for acute respiratory	9
the clinical efficacy	9
required for the	9
into two groups	9
frequency of lqt	9
not in the	9
in the time	9
and lpv r	9
and hcq use	9
observational cohort study	9
admission to the	9
in patients at	9
a significant increase	9
clinical trial efficacy	9
use for covid	9
the mice were	9
and clinical characteristics	9
replication in cell	9
protective effect of	9
maintenance dose of	9
cov and mers	9
the middle east	9
attributed to the	9
infection with oxygen	9
as a binary	9
of disease severity	9
to describe the	9
and qtc prolongation	9
en tiempos de	9
has shown that	9
moderate to severe	9
in the pbs	9
and synthesis of	9
course of disease	9
hcq and azm	9
el momento de	9
mrna expression of	9
major congenital malformations	9
early in the	9
de pointes and	9
durante la pandemia	9
there is still	9
were associated with	9
to an increased	9
is essential for	9
in healthcare settings	9
of this combination	9
due to a	9
these drugs strongly	9
mg on day	9
potential inhibitors of	9
years of age	9
el cual se	9
adverse events were	9
to severe acute	9
treatment in covid	9
at increased risk	9
evaluate the efficacy	9
properties of hcq	9
positive for sars	9
led to a	9
discontinuation of hcq	9
of the total	9
los efectos adversos	9
in saudi arabia	9
for critically ill	9
by using the	9
to increase the	9
and hcq as	9
lack of randomisation	9
observational study conducted	9
that hcq can	9
observational studies and	9
influenza a h	9
lopinavir and ritonavir	9
that the combination	9
toma de decisiones	9
action of hcq	9
the growth of	9
indicated that the	9
of the ace	9
that cq is	9
severe cases of	9
studies with a	9
of either cq	9
cleavage of the	9
the american college	9
inhibited by hcq	9
the assessment of	9
controlled clinical trial	9
clinical trials of	9
green monkey kidney	9
the host cells	9
una estrategia de	9
used in covid	9
with a special	9
assess the efficacy	9
mild to severe	9
coronavirus by chloroquine	9
examine the effect	9
outcomes of critically	9
not been reported	9
of in vitro	9
trials are currently	9
risk of malformations	9
prolongation and refractory	9
hcq with azithromycin	9
from the coronavirus	9
clinical studies have	9
la capacidad de	9
effective against sars	9
to use hcq	9
to patients with	9
approved for the	9
viral rna synthesis	9
from a single	9
of drug treatment	9
may be due	9
in the in	9
seen in the	9
en cuanto a	9
acute kidney injury	9
to the virus	9
shown that hcq	9
is related to	9
ivermectin inhibits the	9
hydroxychloroquine in preventing	9
cases and controls	9
which may be	9
is an urgent	9
been identified as	9
high doses of	9
was determined to	9
hcq appears to	9
be inhibited by	9
the difference in	9
innate and adaptive	9
it is unclear	9
patients who have	9
que no se	9
to the small	9
in hospitalised patients	9
respiratory failure in	9
around the world	9
hydroxychloroquine is associated	9
in observational studies	9
for inhibition of	9
is used in	9
for novel coronavirus	9
these drugs have	9
recommendation to examine	9
potential risk of	9
tener en cuenta	9
disease caused by	9
and combination in	9
of viral load	9
transporting polypeptide a	9
with hcq with	9
boulware et al	9
intensive care units	9
hcq mg twice	9
virological and clinical	9
line with the	9
of intensive care	9
the patients were	9
in reducing the	9
expression levels of	9
summarized in table	9
patients suffering from	9
luego de la	9
treatment of rheumatic	9
of which were	9
total number of	9
for statistical computing	9
time of writing	9
of data from	9
dados de alta	9
after a single	9
and tumor necrosis	9
and prevention of	9
a broad spectrum	9
are included in	9
structure of the	9
phase of the	9
it is worth	9
hcq is not	9
the critically ill	9
combination of these	9
spike glycoprotein and	9
of viral replication	9
the safety profile	9
studies have also	9
with mg kg	9
exposed to hcq	9
associated with disease	9
were reported in	9
wide range of	9
viral clearance and	9
the administration of	9
management of patients	9
inhibition of severe	9
used to predict	9
caused by severe	9
therapy in the	9
the early phase	9
host cells through	9
of transfer to	9
in t cells	9
of the results	9
en el de	9
the high dose	9
management of the	9
of the lung	9
was used in	9
use of a	9
plasma and lung	9
the immune response	9
chronic hydroxychloroquine use	9
should be used	9
in the form	9
human subject research	9
iib clinical trial	9
the propensity score	9
baseline qtc was	9
in plasma and	9
infection in a	9
severe qtc prolongation	9
manejo de pacientes	9
and cq can	9
a recommendation to	9
en el marco	9
la calidad de	9
risk of retinopathy	9
in the past	9
a wide range	9
that the effect	9
chloroquine and covid	9
we need to	9
matched cohort study	9
el personal de	9
of acute respiratory	9
and refractory ventricular	9
with an ec	9
body mass index	9
the prevention and	9
all of the	9
their use in	9
strength of the	9
an et al	9
del uso de	9
randomized controlled studies	9
safety of the	9
large volume of	9
to support the	9
with severe respiratory	9
in an in	9
combination in patients	9
virus replication by	9
been demonstrated that	9
a difference in	9
outcomes such as	9
be responsible for	9
which leads to	9
the process of	9
such as il	9